Schering IL-10 has "very good" efficacy, toxicity data in early clinicals, exec tells Alex. Brown.
Executive Summary
SCHERING-PLOUGH IL-10 EFFICACY, TOXICITY DATA appear to bode well for the biosynthetic interleukin-10 product, Senior VP-Investor Relations and Corporate Communications Geraldine Foster suggested May 14 at the Alex. Brown health care seminar in Baltimore. IL-10 has had "some very good early stage trials in terms of efficacy and lack of toxicity," she said. The product is in clinicals for Crohn's disease and ulcerative colitis. IL-10 also is in early clinicals for rheumatoid arthritis.